Cell and gene therapies (CGT) are a recurring topic for discussions about emerging risks and opportunities in the U.S. healthcare sector. These novel therapies represent incredible scientific advancements, offering hope for people suffering with rare diseases. CGTs also bring considerable uncertainty to health plan and other payers’ financial forecasts. This report shares our experience in gathering evidence to help inform key components necessary for any financial forecast, and is arranged in five sections:

• Introduction to CGT
• Pipeline identification 
• Approval timing and cost 
• Treatment-eligible population 
• Rate of treatment